TrialBlood advances2024

Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study.

Marco Herling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.